Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link It Is a Huge Market. The Pipeline Is Full. More GLP 1s Are On Their Way. Managed Healthcare Executive Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Triple Agonism Based Therapies for Obesity Current Cardiovascular Risk Reports Springer Nature Link Cagrilintide Semaglutide Blend 5+5mg for Sale Cagri Sema GIPR GLP 1R dual agonist therapies for diabetes and weight losschemistry, physiology, and clinical applications ScienceDirect